1 active not recruiting, 1 approved for marketing, 1 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Tiratricol: new trials by email Literature Review of Tiratricol trials Research Report on Tiratricol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) Tiratricol, Placebo - Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome | Phase 3 | Completed | Rare Thyroid Therapeutics International AB | 20 | 2023-07-21 | 2026-04-08 |
| Triac Trial II in MCT8 Deficiency Patients Tiratricol - Allan-Herndon-Dudley Syndrome | Phase 2 | Active not recruiting | Rare Thyroid Therapeutics International AB | 22 | 2020-12-07 | 2026-02-20 |
| Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency Tiratricol - Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome | Approved for marketing | Rare Thyroid Therapeutics International AB | 2026-10-06 |
Allan-Herndon-Dudley syndrome (3)
Rare Thyroid Therapeutics International AB (3)
United States (3) · Netherlands (2) · Czechia (1) · Germany (1) · United Kingdom (1)
Andrew Bauer, MD (1) · Andrew J. Bauer, MD (1) · Heiko Krude (1) · Jan Lebl (1) · Lindsey Nicol (1) · W. E. Visser, MD (1) · W.E. Visser, MD, PhD (1)